NDC 82293-032-30 - everolimus
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 82293-032
- Requested NDC
- 82293-032-30
- Package NDCs from labels
- 82293-032-10, 82293-032-20, 82293-032-21, 82293-032-30, 82293-032-31
- Manufacturer
- Novugen Pharma (USA) LLC. | Novugen Oncology Sdn. Bhd. | Novugen Oncology Sdn Bhd
- Effective date
- 2026-03-10
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| everolimus - Novugen Pharma (USA) LLC. | Novugen Oncology Sdn. Bhd. | Novugen Oncology Sdn Bhd | Novugen Pharma (USA) LLC. | Novugen Oncology Sdn. Bhd. | Novugen Oncology Sdn Bhd | 2026-03-10 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 82293-032-10 | everolimus | 28 in 1 BOTTLE | TABLET | 28 | 1 | |
| 82293-032-20 | everolimus | 7 in 1 BLISTER PACK | TABLET | 7 | 1 | |
| 82293-032-21 | everolimus | 4 in 1 CARTON | TABLET | 4 | 1 | |
| 82293-032-30 | everolimus | 10 in 1 BLISTER PACK | TABLET | 10 | 1 | |
| 82293-032-31 | everolimus | 1 in 1 CARTON | TABLET | 1 | 1 | |
| 82293-032-31 | everolimus | 3 in 1 POUCH | TABLET | 3 | 1 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 82293-032-20 | EA - Each | 82293-032 | 5b444db9-68bb-445e-9b8c-ded4a1beada0 | 1 | 2026-05-22 |
| 82293-032-21 | EA - Each | 82293-032 | 7cc71094-2a6c-4c87-9435-e354102ecd53 | 1 | 2026-05-22 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anubis Barcelona Vital Line | HYDROLYZED ELASTIN, HYDROLYSED COLLAGEN, COCOGLYCERIDES | ANUBIS COSMETICS SL | ebe024f7-7c45-ad60-e053-2995a90a45d6 | 2023-09-01 | Warnings | 1P9D0Z171K |
| Anubis Barcelona Protective Line | ETHYLHEXYL METHOXYCINNAMATE, BUTYL METHOXYDIBENZOYLMETHANE, ETHYLHEXYL SALICYLATE, OCTOCRYLENE | ANUBIS COSMETICS SL | ec83846f-11c0-8f59-e053-2995a90ab9d2 | 2023-09-01 | Warnings | 1P9D0Z171K |
| Anubis Barcelona Regul Oil | CETEARYL ETHYLHEXANOATE, PROPYLENE GLYCOL, GLYCERYL STEARATE SE | ANUBIS COSMETICS SL | eb68c3ab-7835-1a1c-e053-2995a90a0d66 | 2023-09-01 | Warnings | 1P9D0Z171K |
| Anubis Barcelona Spa Line | ORYZA SATIVA (RICE) STARCH, PERLITE, PALMITIC ACID | ANUBIS COSMETICS SL | eb01a962-ab38-18ec-e053-2995a90acdeb | 2023-09-01 | Warnings | 1P9D0Z171K |
| Everolimus | EVEROLIMUS | Natco Pharma Limited | e3dbbc24-7e55-4069-a305-e2cded2db641 | 2023-06-08 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.